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Cerebral venous/sinus thrombosis (CVT) is an uncommon
disease which accounts for 0.5-1% of all strokes. Despite ad-
vances in the recognition of CVT, diagnosis is frequently
overlooked or delayed as a result of the wide spectrum of
clinical symptoms. Moreover, there is an absence of a uni-
form diagnostic and treatment approach. However, in past
two years several guidelines about management of CVT
have been published. 
Diagnostic approach: In the initial clinical assessment, it is
recommended to perform screening for potential pro-
thrombotic conditions that may predispose a person to
CVT. A normal D-dimer level may help to identify patients
with a low probability of CVT. A venographic study (CTV
or MRV) should be performed in suspected CVT if the
plain CT or MRI is negative. Gradient echo T2 susceptibil-
ity-weighted images combined with MR can be useful to
confirm CVT diagnosis. A follow-up CTV or MRV at 3 to
6 months after diagnosis is reasonable to assess for recanal-
ization of the occluded vein/sinuses.
Therapeutic approach: Initial anticoagulation with unfrac-
tioned heparin or low-molecular weight heparin in full an-
ticoagulant doses is reasonable, followed by vitamin K
antagonists, regardless of the presence of intracerebral hem-
orrhage. Endovascular intervention may be considered if de-
terioration occurs despite intensive anticoagulation treat-
ment. For patients with CVT, steroid medications are not
recommended, even in the presence of parenchymal brain
lesions on CT/MRI, unless needed for another underlying
disease.
In patients with provoked CVT vitamin K antagonists may
be continued for 3 to 6 months, in patients with unpro-
voked CVT, vitamin K antagonists may be continued for 6
to 12 months and for patients with recurrent CVT or first
CVT with severe thrombophilia, indefinite anticoagulation
may be considered, with a target INR of 2-3.
Patients with CVT and a suspected bacterial infection
should receive appropriate antibiotics. In patients with CVT
and increased intracranial pressure, monitoring for progres-
sive visual loss is recommended, and when this is observed,
increased intracranial pressure should be treated urgently. It
is reasonable to initiate treatment with acetazolamide in such
patients. In patients with CVT and a single seizure with
parenchymal lesions, early initiation of antiepileptic drugs
for a defined duration is recommended to prevent further
seizures. In the absence of seizures, the routine use of
antiepileptic drugs in patients with CVT is not recom-
mended.
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